From: Specific genomic aberrations in primary colorectal cancer are associated with liver metastases
 |  | M0 |  |  | PM |  |  | LM |  |  | p-value** |
---|---|---|---|---|---|---|---|---|---|---|---|
 |  | 25 | Percentage |  | 37 | Percentage |  | 36 | Percentage |  |  |
Gender | Male | 14 | 56% | Â | 21 | 57% | Â | 27 | 75% | Â | Â |
 | Female | 11 | 44% |  | 16 | 43% |  | 9 | 25% |  | 0,185 |
Mean age at diagnosis | Â | Â | Â | 64,21 | Â | Â | 53,23 | Â | Â | 54,66 | Â |
Location primary tumor | Right colon | 11 | 44% | Â | 11 | 30% | Â | 4 | 11% | Â | Â |
 | Left colon | 9 | 36% |  | 22 | 59% |  | 22 | 61% |  |  |
 | Rectum | 5 | 20% |  | 4 | 11% |  | 10 | 28% |  | 0,027 |
T-status | T1 | 0 | 0% | Â | 0 | 0% | Â | 0 | 0% | Â | Â |
 | T2 | 0 | 0% |  | 1 | 3% |  | 4 | 11% |  |  |
 | T3 | 21 | 84% |  | 25 | 67% |  | 30 | 84% |  |  |
 | T4 | 4 | 16% |  | 11 | 30% |  | 1 | 3% |  | 0,01 |
 | unknown | 0 | 0% |  | 0 | 0% |  | 1 | 3% |  |  |
N-status | N0 | 19 | 76% | Â | 17 | 47% | Â | 13 | 36% | Â | Â |
 | N+ | 6 | 24% |  | 19 | 53% |  | 22 | 61% |  | 0,01 |
 | unknown | 0 | 0% |  | 0 | 0% |  | 1 | 3% |  |  |
Stage | 1 | 0 | 0% | Â | 1 | 3% | Â | 0 | 0% | Â | Â |
 | 2 | 16 | 64% |  | 5 | 13% |  | 3 | 8% |  |  |
 | 3 | 9 | 36% |  | 13 | 35% |  | 7 | 20% |  |  |
 | 4 | 0 | 0% |  | 18 | 49% |  | 26 | 72% |  | 0 |
Presentation | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0,009 |
 | Metachrone | 25 | 100% |  | 19 | 51% |  | 8 | 22% |  |  |
 | Synchrone |  |  |  | 18 | 49% |  | 26 | 72% |  |  |
 | Unknown |  |  |  | 0 | 0% |  | 2 | 6% |  | 1,00E-06 |
Differentiation | Good | 0 | 0% | Â | 3 | 8% | Â | 3 | 12% | Â | Â |
 | Moderate | 21 | 88% |  | 27 | 73% |  | 17 | 65% |  |  |
 | Poor | 3 | 13% |  | 5 | 14% |  | 6 | 23% |  |  |
 | Other type | 0 | 0% |  | 2 | 5% |  | 0 | 0% |  | 0,3 |
Overall survival | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Median in months (range) | Â | Â | Â | 103 (12-279) | Â | Â | 22 (2-120) | Â | Â | 26 (0-108) | Â |
MSI status | Stable | 21 | 91% | Â | 33 | 97% | Â | 30 | 100% | Â | Â |
 | Low | 2 | 9% |  | 0 | 0% |  | 0 | 0% |  |  |
 | High | 0 | 0% |  | 1 | 3% |  | 0 | 0% |  | 0,124 |
Adjuvant treatment | No | 16 | 64% | Â | 25 | 68% | Â | 34 | 94% | Â | Â |
 | Chemo | 6 | 24% |  | 12 | 32% |  | 2 | 6% |  |  |
 | Unknown | 3 | 12% |  | 0 | 0% |  | 0 | 0% |  | 0,014 |